JP2024520435A5 - - Google Patents
Info
- Publication number
- JP2024520435A5 JP2024520435A5 JP2023572827A JP2023572827A JP2024520435A5 JP 2024520435 A5 JP2024520435 A5 JP 2024520435A5 JP 2023572827 A JP2023572827 A JP 2023572827A JP 2023572827 A JP2023572827 A JP 2023572827A JP 2024520435 A5 JP2024520435 A5 JP 2024520435A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- days
- day
- composition according
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163194026P | 2021-05-27 | 2021-05-27 | |
| US63/194,026 | 2021-05-27 | ||
| PCT/US2022/031055 WO2022251441A1 (en) | 2021-05-27 | 2022-05-26 | Methods of treating multiple myeloma using combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024520435A JP2024520435A (ja) | 2024-05-24 |
| JP2024520435A5 true JP2024520435A5 (https=) | 2025-05-30 |
Family
ID=82067750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023572827A Pending JP2024520435A (ja) | 2021-05-27 | 2022-05-26 | 組み合わせ療法を用いて多発性骨髄腫を治療する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240252487A1 (https=) |
| EP (1) | EP4347037A1 (https=) |
| JP (1) | JP2024520435A (https=) |
| KR (1) | KR20240013793A (https=) |
| CN (1) | CN117440828A (https=) |
| AU (1) | AU2022282372A1 (https=) |
| BR (1) | BR112023022679A2 (https=) |
| CA (1) | CA3215840A1 (https=) |
| IL (1) | IL307681A (https=) |
| MX (1) | MX2023012911A (https=) |
| WO (1) | WO2022251441A1 (https=) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8628927B2 (en) | 2008-11-07 | 2014-01-14 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
| EP4467143B1 (en) * | 2017-07-10 | 2026-03-11 | Celgene Corporation | Method for preparing 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile |
| WO2020146441A1 (en) | 2019-01-09 | 2020-07-16 | Celgene Corporation | Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same |
| FI3908281T3 (fi) | 2019-01-09 | 2024-10-01 | Celgene Corp | Antiproliferatiivisia yhdisteitä ja toisia aktiivisia aineita käytettäväksi multippelin myelooman hoidossa |
| SG11202107439XA (en) | 2019-01-09 | 2021-08-30 | Celgene Corp | Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same |
-
2022
- 2022-05-26 KR KR1020237044752A patent/KR20240013793A/ko active Pending
- 2022-05-26 US US18/563,037 patent/US20240252487A1/en active Pending
- 2022-05-26 IL IL307681A patent/IL307681A/en unknown
- 2022-05-26 AU AU2022282372A patent/AU2022282372A1/en active Pending
- 2022-05-26 BR BR112023022679A patent/BR112023022679A2/pt unknown
- 2022-05-26 EP EP22731023.2A patent/EP4347037A1/en active Pending
- 2022-05-26 MX MX2023012911A patent/MX2023012911A/es unknown
- 2022-05-26 CA CA3215840A patent/CA3215840A1/en active Pending
- 2022-05-26 WO PCT/US2022/031055 patent/WO2022251441A1/en not_active Ceased
- 2022-05-26 JP JP2023572827A patent/JP2024520435A/ja active Pending
- 2022-05-26 CN CN202280036385.XA patent/CN117440828A/zh active Pending